CRP and renal cell carcinoma: Among these, CRP, which is a serum marker of systemic inflammation, showed promise as a prognostic tool in patients with renal cell carcinoma.[19] Pilskog et al confirmed that baseline CRP may be a useful biomarker in mRCC treatment plans.[20] Kalogirou et al demonstrated the effectiveness of determining preoperative CRP level as a prognostic marker of survival in a cohort of patients with mRCC undergoing cell-reducing nephrectomy (CN).[21]